The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been shown to induce apoptosis in various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are resistant to the natural alltrans retinoic acid and to many synthetic receptorselective retinoids. Although the mechanism of this eect was not elucidated, it was found to be independent of nuclear retinoid receptors. In the present study, we analysed the mechanisms by which CD437 induces apoptosis in two human NSCLC cell lines: H460 with wild-type p53 and H1792 with mutant p53. Both cell lines underwent apoptosis after exposure to CD437, although the cell line with wild-type p53 (H460) was more sensitive to the induction of apoptosis. CD437 increased the activity of caspase in both cell lines, however, the eect was much more pronounced in the H460 cells. The caspase inhibitors (Z-DEVD-FMK and Z-VAD-FMK) suppressed CD437-induced CPP32-like caspase activation and apoptosis in both cell lines. CD437 induced the expression of the p53 gene and its target genes, p21, Bax, and Killer/DR5, only in the H460 cells. These results suggest that CD437-induced apoptosis is more extensive in NSCLC cells that express wild-type p53, possibly due to the involvement of the p53 regulated genes Killer/DR5, and Bax although CD437 can also induce apoptosis by means of a p53-independent mechanism. Both pathways of CD437-induced apoptosis appear to involve activation of CPP32-like caspase.
Introduction
In the United States, lung cancer leads all other cancers in both incidence and mortality. Since 1987, more women have died of lung cancer than breast cancer (Landis et al., 1998) . Unfortunately, the severe morbidity of lung cancer and the poor 5-year relative survival rate (only 14%) have not been improved by current treatments. Therefore, new approaches for prevention and treatment of lung cancer have to be urgently explored. One promising approach being studied in a variety of clinical trials is chemoprevention, the administration of drugs to block or prevent the development of cancer (Benner et al., 1995) .
Retinoids are a class of natural and synthetic vitamin A analogues known to play a major role in regulating growth and dierentiation of normal, benign, and malignant cell types (DeLuca, 1991) . Retinoids have promising potential for use in the prevention of lung cancer (Benner et al., 1995) , however, the broad biological activities of natural retinoids lead to a number of undesirable side eects that limit their long-term clinical use as chemopreventive agents. It is thought that retinoids act by activation of gene transcription by nuclear retinoid receptors of two types, retinoic acid receptors (RARs) and retinoid X receptors (RXRs) (Chambon, 1996) . The discovery that nuclear retinoid receptors act as mediators of most of retinoid actions (Chambon, 1996) raised the hope that retinoids whose receptor selectivity is restricted to speci®c RAR or RXR subtypes (a, b, and g) may have fewer side eects than natural retinoids and could eventually be developed for cancer prevention or therapy (Lehmann et al., 1991) . One such retinoid is 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437), which is RARgselective (Bernard et al., 1992) and has been shown to inhibit the growth of lung cancer (Sun et al., 1997a; Adachi et al., 1998; Li et al., 1998) , cervical cancer (Oridate et al., 1997) , breast cancer (Shao et al., 1995) , leukemia (Hsu et al., 1997) , and melanoma (Schadendorf et al., 1996) cells.
The majority of human lung cancer cell lines in vitro exhibit profound resistance to all trans retinoic acid (ATRA) treatment (Geradts et al., 1993) . Recently, we found that CD437 was the most active among 37 nuclear receptor-selective retinoids in inhibiting several ATRA-resistant human non-small cell lung carcinoma (NSCLC) cell lines via induction of apoptosis (Sun et al., 1997a,b) . Although the biological activities of retinoids are thought to be mediated by nuclear retinoid receptors and CD437 can selectively bind to and transactivate the RARg receptor (Bernard et al., 1992) , its action on induction of apoptosis is independent of the RAR-mediated pathway, as was demonstrated in lung (Sun et al., 1997a) and breast (Shao et al., 1995) cancer cells.
Apoptosis is a tightly regulated process involving changes in the expression of distinct genes (Martin and Green, 1995) . The mechanism by which retinoids induce apoptosis in normal or malignant cells is not yet well de®ned (Lotan, 1995) . p53, as well as its modulated genes such as p21, Bax, and Killer/DR5, are thought to play an important role in the control of apoptosis (Shimanmura and Fisher, 1996; Wu et al., 1997) . In human breast cancer cells, CD437 induces G0/G1 arrest and apoptosis via a unique pathway that seems to involve regulation of known downstream eectors of p53 such as p21, Bcl-2, and Bax in a p53-independent manner (Shao et al., 1995) . To explore the possible mechanisms of CD437-induced apoptosis in human NSCLC cells, we studied two cell lines with either wild-type or mutant p53. Our results indicate that p53-dependent and -independent mechanisms are involved in CD437-induced apoptosis, depending on the cell line. We also found that CPP32-like caspase activation is required for CD437-induced apoptosis in both NSCLC cell lines.
Results

Induction of apoptosis by CD437
After cells were exposed to 1 mM CD437 for 24 h to 72 h, they shrank, rounded up and detached from the dishes (¯oated) (data not shown), which suggested that the cells underwent apoptosis. To con®rm this supposition, we analysed apoptosis following exposure to 1 mM CD437 using dierent approaches. CD437-induced DNA fragmentation in the two NSCLC cell lines was ®rst assessed using an enzyme-linked immunosorbent assay (ELISA), which quantitatively and speci®cally detects cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) occurring during apoptosis. Both cell lines had increased levels of histone-associated DNA fragments following exposure to CD437 (1 mM) for 24 h. However, the DNA fragments were elevated more than sixfold in H460 cells but less than twofold in H1792 cells ( Figure  1a) . Similar results were also obtained by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-¯ow cytometry, which measures terminal deoxynucleotidyl transferase (TdT)-dependent incorporation of¯uorescein-conjugated dUTP to the 3'-hydroxyl ends of double-or single-stranded DNA (Figure 1b) . Together, these results clearly indicated that both cell lines underwent apoptosis but that H460 cells were much more sensitive to CD437-induced apoptosis than H1792 cells.
CPP32-like caspase activation and poly(ADP-ribose)polymerase (PARP) cleavage by CD437
Activation of caspase-3 (CPP32) and proteolysis are hallmarks of apoptosis (Patel et al., 1996) . To determine whether caspase was activated in NSCLC cells by CD437 exposure, we measured CPP32-like caspase activity in cytosolic extracts from H1792 and H460 cells treated with 1 mM CD437 for 24 h. As shown in Figure 2a , the CPP32-like caspase activity was elevated in both cell lines, although this activity was increased much more in H460 cells (10.8-fold) than in H1792 cells (2.6-fold); this result paralleled the increase in CD437-induced apoptosis (Figure 1 ). Furthermore, we analysed cleavage of PARP, one of the substrates of CPP32 proteolysis, in cell extracts from H1792 and H460 cells treated with CD437 by Western blotting. An 89 kD fragment cleaved from the 113 kD PARP was detected in extracts from H460 cells treated with CD437 at concentrations of 0.5 mM or greater for 24 h but in extracts from H1792 cells only when they were treated with CD437 at concentrations of 2.5 mM or greater (Figure 2b ). The 89 kD PARP fragment was detected as early as 12 h in H460 cells (Figure 2c ) but not at 24 h in H1792 cells (data not show) after cells were treated with 1 mM CD437. However, longer treatment of H1792 cells (for 48 h) with CD437, even at 0.5 mM, induced 89 kD fragment (Figure 2d ). These results indicate that CD437 activates CPP32 or CPP32-like caspase in NSCLC cells to various degrees, in parallel with its ability to induce apoptosis.
Caspase inhibitors suppress CD437-induced CPP32-like caspase activation and apoptosis Although caspase activation and proteolysis are hallmarks of apoptosis, inhibition of caspases does not always prevent cells from undergoing apoptosis, suggesting the existence of a caspase-independent pathway. To further investigate the role of caspases in CD437-induced apoptosis in NSCLC cells, H460 and H1792 cells were treated with 1 and 2 mM of Figure 1 Induction of apoptosis by CD437 in human NSCLC cells. Cells were seeded in 10 cm dishes or 24-well plates and harvested after 24 h of treatment with 1 mM CD437. Apoptosis was evaluated by ELISA for cytoplasmic histone-associated DNA fragments (a) and by the TUNEL assay for DNA breaks with 3'-hydroxyl ends (b) as described in Materials and methods. Bars (in a) indicate means+s.d. of duplicate determinations CD437, respectively, in the absence or presence of 100 mM caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK. As shown in Figure 3a , CD437-induced CPP32-like caspase activation was suppressed in both cell lines. At the same time, CD437-induced apoptosis was also inhibited in these cell lines (Figure 3b ). These results indicate that CPP32 or CPP32-like caspase activation is necessary for CD437-induced apoptosis in these NSCLC cells.
Changes in cell cycle after exposure to CD437
Previous studies with breast cancer cells have shown that CD437 caused a G0/G1 arrest (Shao et al., 1995) . To determine whether a similar eect was induced in NSCLC cells, we analysed cell cycle distribution of cells after CD437 treatment. In the absence of CD437, the proportion of cells in the G1 phase increased with time in both cell lines with a concomitant decrease in S phase. However, as shown in Figure 4 , changes in the cell cycle by CD437 varied with the cell line. After 4 h of treatment with 1 mM CD437, the proportion of H1792 cells in G1 phase increased and in S phase decreased, however, subsequently (after 8 h), there was a decrease in cells in G1 and G2/M with a concomitant increase of cells in S phase and the cells were arrested in S phase after 12 h ( Figure 4a ). In contrast, H460 cells showed an increase in G1 after 4 h and at later times, whereas the proportion of cells in S and G2/M decreased ( Figure 4b ).
Modulation of p53 expression by CD437
The results described above indicated that H460 cells with wild-type p53 were more sensitive to CD437 than H1792 with mutant p53, therefore, we investigated further whether there was a relationship between p53 status and response to CD437. As demonstrated in Figure 5 , in H1792 cells there was no detectable p53 mRNA or protein either before or after CD437 treatment. However, in H460 cells, CD437 (1 mM) increased p53 protein expression as early as 3 h after exposure without changing p53 mRNA levels suggesting a post-transcriptional mechanism for increased levels of p53 protein by CD437.
Modulation of p21 expression by CD437
p21, a downstream gene target of p53, regulates cell growth or death . Therefore, we examined the modulation of p21 expression by CD437 in the two cell lines. Increased p21 mRNA after ) were assayed for CPP32-like caspase activity using the ApoAlert CPP32 fluorescent assay kit (a), and 1610 5 cells were assayed for apoptosis using ELISA (b) as described in Materials and methods. Data represent the means+s.d. of triplicate (b) and duplicate (b) determinations treatment with 1 mM CD437 was found in both cell lines. At the protein level, signi®cant induction of p21 by CD437 was detected in H460 cells but not in H1792 cells, where no protein could be detected despite the increase in mRNA ( Figure 5 ). The induction of p21 protein in H460 cells occurred as early as 3 h and and in parallel with the increase in p53 protein.
Modulation of Killer/DR5 expression by CD437
Killer/DR5 is a recently identi®ed, p53-modulated celldeath receptor gene that may play an important role in p53-mediated apoptosis (Wu et al., 1997) . We found that Killer/DR5 mRNA was induced by 1 mM CD437 in a time-and dose-dependent manner in H460 cells, starting at 3 h (Figure 6a and c) . However, the induction of Killer/DR5 mRNA by the same concentration of CD437 was much smaller in H1792 cells (Figure 6b and  c) . Furthermore, we found that Killer/DR5 mRNA was speci®cally induced only by CD437 and not by other retinoids such as 4-(N-hydroxyphenyl)retinamide (4HPR), ATRA, CD666 and LG1069 even at 10 mM (Figure 7 ). Unlike CD437, ATRA, CD666 and LG1069 did not induce apoptosis in the NSCLC cells even at 10 mM. However, 4HPR, another synthetic retinoid, can induce apoptosis in human lung cancer (Zou et al., 1998) , but did not induced Killer/DR5. Figure 4 Changes in cell cycle induced by CD437 in H1792 (a) and H460 (b) cells. Cells were seeded in 10-cm dishes and treated with 1 mM CD437. Attached cells were harvested at indicated times and analysed by¯ow cytometry after staining with propidium iodide as described in Materials and methods
Figure 5
Modulation of p53 and p21 expression by CD437 in NSCLC cells. Cells were treated with 1 mM of CD437 for the indicated times on the second day after seeding. Total cellular RNA and whole cell lysates were prepared. Northern and Western blot analyses were performed as described in Materials and methods. GAPDH and b-actin were used as loading control for Northern and Western blotting, respectively. PC, positive control (lysate from H460 cells treated with 1 mM CD437 for 24 h) The proteins Bcl-2, Bcl-x L , and Bax are important components of the apoptotic pathway that act as either negative or positive regulators of apoptosis . Using Western blot techniques, we investigated Bcl-2, Bcl-x L and Bax protein expression after H460 and H1792 cells were exposed to 1 mM CD437. CD437 did not change the expression of Bcl-2 or Bcl-x L in either of the cell lines (Figure 8a ). In our study, two sizes of Bax proteins (about 23 kD and 20 kD) were detected. The 20 kD bax was also detected in control untreated cells after longer exposure (data not shown). Therefore, we suggest that these two bands are likely to represent the Bax isoforms a (20 kD) and b (23 kD) . CD437 induced the expression of Bax a in H460 cells treated for 24 h. We further performed Northern blotting to determine whether CD437 can upregulate Bax mRNA expression in NSCLC cells. As shown in Figure 8b and c, Bax mRNA was upregulated by CD437 in H460 cells, starting from 12 h. This upregulation of Bax by CD437 was not observed in H1792 cells.
Modulation of tissue transglutaminase (TGase II) expression by CD437
TGase II is another p53-related, retinoid-regulated apoptotic gene (Lu et al., 1994; Nagy et al., 1998) . We did not detect TGase II mRNA in H460 cells, nor did CD437 treatment induce TGase II mRNA expression in this cell line (data not shown). In contrast, H1792 cells, which have mutant p53, expressed TGase II mRNA, the expression of which could be upregulated by CD437 in a time dependent manner (data not shown).
Discussion
CD437, a RARg-selective retinoid, was reported to induce apoptosis in dierent human cancer cell lines. Several studies have concluded that nuclear retinoid receptors are not involved in the mechanism by which CD437 induces apoptosis, however, its mechanism of action remains unclear (Shao et al., 1995; Schadendorf et al., 1996; Sun et al., 1997a; Oridate et al., 1997; Hsu et al., 1997; Adachi et al., 1998; Li et al., 1988) . In the present study, two human NSCLC cell lines (H460 and H1792, with wild-type and mutant p53, respectively) (Mitsudomi et al., 1992) were used to explore the mechanisms of CD437-induced apoptosis in NSCLC cells. H460 cells exhibited higher DNA fragmentation after a short exposure to CD437 than did H1792 cells. The latter cells eventually also underwent apoptosis, albeit relatively later and to a lesser extent. These ®ndings suggest that the cells which possess wild-type p53 are more susceptible to CD437-induced apoptosis than cells with mutant p53. Other studies have demonstrated that cells with wild-type p53 have increased sensitivity to radiation or chemotherapeutic agents, whereas cells lacking wild-type p53 expression still undergo apoptosis but need a relatively high dose of radiation or chemotherapeutic drugs (Lowe et al., 1993; Lee and Bernstein, 1993; Fan et al., 1994) . Thus, apoptosis may be induced by both p53-dependent or p53-independent mechanisms (Liebermann et al., 1995) . Besides the dierence in the status of the constitutive p53 between the two cell lines, in H460 cells, CD437 caused an early increase of p53 protein levels, which may explain why these cells were more sensitive to CD437 than H1792 cells. Our ®ndings with the H460 cells con®rm a recent report on an increase in p53 protein in lung cancer cells treated with CD437 (Adachi et al., 1998) . In contrast with our ®ndings, elevated p53 levels were not found in breast cancer cell lines with either wild-type or mutant p53 after incubation with CD437 (Shao et al., 1995) , indicating that lung cancer cells and breast cancer cells may respond dierently to CD437 and that p53 may play an important role in CD437-induced apoptosis in some NSCLC cells.
The most important roles of p53 are to induce growth arrest and apoptosis (Shimanmura and Fisher, 1996; Liebermann et al., 1995) . It is well documented that p53 mediates these eects by transactivation of downstream eector genes after directly binding to DNA in a sequence-speci®c manner (Shimanmura and Fisher, 1996; Liebermann et al., 1995) . For example, p21, one of the genes regulated by wild-type p53, has been shown to induce G1 arrest by inhibition of cyclindependent kinase and PCNA-dependent DNA replication Chen et al., 1995) . Exposure of cells to DNA-damaging agents leads to p53-dependent induction of p21 expression, resulting in growth arrest or apoptosis . In addition, induction of p21 can occur by p53-independent mechanisms in response to mitogenic stimuli, in response to dierentiation, or in tumor cells with mutant p53 (Michieli et al., 1994; Sheikh et al., 1994) . p21 is believed to mediate, at least in part, p53-induced changes in the cell cycle. However, the role of p21 in apoptosis is less clear. p21 has been postulated to be a critical player in the apoptotic process in some cell types . However, there are other cell types where p21 provides protection from undergoing apoptosis (Polyak et al., 1996; Gomez-Manzano et al., 1997) . Thus, the role of p21 in apoptosis may depend on cell context. In our study, CD437 increased p21 mRNA levels in both cell lines; however, the level of CD437-induced p21 mRNA was higher in H460 cells than in H1792 cells. p21 protein induction was increased by CD437 in H460 cells but no protein was detected in H1792 cells. The induction of p21 mRNA by CD437 in H1792 cells was obviously p53 independent. It is plausible but not proven that p21 mRNA and protein induction by CD437 in H460 cells was related to the presence of wild-type p53.
Changes in the cell cycle after CD437 treatment were distinct for each of the cell lines. G1 arrest by CD437 was observed only at early times in H460 cells, in which p21 protein expression was increased. In contrast, G1 phase was dramatically decreased (after a temporary increase at 4 h of treatment) and S phase strikingly increased by CD437 treatment in H1792 cells, in which p21 protein was neither expressed nor induced. These results are dierent from those obtained with human breast cancer cells in which CD437 arrested cells in the G1 phase (Shao et al., 1995) . Moreover, the fact that both H460 and H1792 cells underwent apoptosis when treated with CD437 regardless of the dierence in the eects of CD437 on their cell cycle suggests that G1 arrest may not be necessary for CD437-induced apoptosis in NSCLC cells. Therefore, we proposed that p21 induction may lead to G1 arrest and possibly also apoptosis in H460 cells but is not important in CD437-induced apoptosis in H1792 cells. Adachi et al. (1998) have shown recently that CD437-induced G1 arrest in H460 cells involved inhibition of Rb hyperphosphorylation and reduction in cdk2 and cdk4 activities and could be mediated by the increase in p21. Recently, we have compared the eects of CD437 on cell cycle in more NSCLC cell lines and found that G1 arrest was observed in three cell lines with wild-type p53 but not in ®ve cell lines with mutant p53 after CD437 treatment. The increase in p21 expression also occurred only in the three cell lines with wild-type p53. Therefore, we propose that cells expressing wild-type p53 accumulate in G1 after CD437 treatment, perhaps by the action of p21.
The Bax gene is another downstream gene regulated by wild-type p53 (Miyashita and Reed, 1995) . Shao et al. (1995) showed that CD437 upregulated Bax mRNA expression in human breast cancer cells but they did not analyse Bax protein level. Adachi et al. (1998) reported that CD437 did not change the expression of Bax protein in human lung cancer cells, including H460 cells but they did not analyse the mRNA level. Our results showed that CD437 not only upregulated the expression of Bax mRNA but also increased the expression of Bax a protein in H460 with wild-type p53 but not in H1792 with mutant p53. Bax, which promotes cell death, functions through the formation of heterodimers with Bcl-2, which prevents cell death. It has been suggested that the ratio of Bax to Bcl-2 determines cell survival or death following an apoptotic stimulus . Our study shows that CD437 did not change either Bcl-2 or Bclx L (another anti-apoptotic protein) expression, suggesting that both genes are not involved in CD437-induced apoptosis in NSCLC cells. Because Bax protein was increased in CD437-treated H460 cells only after 24 h, its role in the early stages of the apoptotic process, which is detected by 12 h, may not be as important as that of other proapoptotic molecules such as Killer/ DR5.
The Killer/DR5 gene was recently identi®ed as a novel p53-modulated death receptor gene (Wu et al., 1997) that may play an important role in p53-mediated apoptosis. Our study shows for the ®rst time that CD437 can induce Killer/DR5 mRNA expression in a time-and dose-dependent manner in H460 cells but not in H1792 cells, suggesting that CD437-induced Killer/ DR5 expression is dependent on p53 status. These results also suggest the involvement of p53 and Killer/ DR5 in CD437-induced apoptosis in H460 cells. In addition, we found that other retinoids such as ATRA, CD666, and LG1069 failed to induce Killer/DR5 expression even at 10 mM. Except for 4HPR, these retinoids also failed to induce apoptosis. 4HPR, another synthetic retinoid that can induce apoptosis in human lung cancer cells (Zou et al., 1998) , decreased cell survival at 10 mM, but did not induced Killer/DR5 expression at this concentration. These results indicate that CD437-induced Killer/DR5 expression is speci®c and is correlated with the induction of apoptosis by a mechanism that may be dierent from that of 4HPR.
Recently, we examined the eects of CD437 on apoptosis induction in eight NSCLC cell lines. CD437 upregulated the expression of Killer/DR5, Bax and p21 and induced rapid apoptosis in three cell lines (A549, H460 and H1944) with wild-type p53 but not in cell lines (H596, H157, Calu-1, H522 and H1792) with mutant p53. Similar to the ®nding in this study, longer treatment was needed for CD437 to exert apoptosisinducing eect on the cell lines with mutant p53 (Sun et al., unpublished data) . Thus, the increase in the downstream target genes of p53 appears to be a common mechanism for CD437-induced, p53-dependent apoptosis.
Because H1792 cells have a mutant p53 and because no expression of the p53-regulated genes (such as p21 and Killer/DR5) was induced by CD437 in this cell line, CD437-induced apoptosis in H1792 cells is obviously independent of these genes. TGaseII is another p53-regulated, apoptosis-related gene (Nagy et al., 1998) . However, TGaseII does not appear to be involved in the p53-dependent apoptotic pathway because p53 negatively regulates (i.e. inhibits) TGaseII expression (Lu et al., 1994) . TGaseII mRNA was not detected in H460 cells, which express wild-type p53, nor did CD437 induce TGaseII mRNA expression in H460 cells. However, TGaseII mRNA was expressed in H1792 cells, which have mutant p53, and this expression was upregulated by CD437 treatment. Therefore, TGaseII induction may contribute to CD437-induced, p53-independent apoptosis in H1792 cells.
Current evidence indicates that proteases could be central components of the cell death machinery in various forms of apoptosis (Patel et al., 1996) . Of the ten known caspases, caspase-3 or CPP32 is one of the strongest candidates for being a mammalian cell deathinducing protease that cleaves PARP and other vital proteins (Patel et al., 1996) . Recently, Piedra®ta and Pfahl (1997) reported that apoptosis induced by certain retinoids (including CD437) in the T-cell lines EL-4 and Jurkat requires activation of caspases (2 and 3). In our NSCLC cells, CD437 induced CPP32-like caspase activation and PARP cleavage in parallel with induction of apoptosis. Furthermore, caspase inhibitors suppressed both CD437-induced CPP32-like caspase activation and CD437-induced apoptosis in both NSCLC cell lines. These results indicate that CPP32 or CPP32-like caspase activation is required for CD437-induced apoptosis in the two NSCLC cell lines.
In conclusion, we assert that CD437 induces either p53-dependent or -independent apoptosis in human NSCLC cells, depending on the cell line and that caspase (CPP32 or CPP32-like) activation is necessary for both types of apoptosis induced by CD437 in NSCLC cells.
Materials and methods
Chemicals
CD437 and CD666 were synthesized by CIRD/Galderma (Sophia Antipolis, France). ATRA was obtained from Dr Werner Bollag (F Homann-La Roche, Basel, Switzerland).
LG1069 was provided by Richard Heyman (Ligand Pharmaceuticals, San Diego, CA, USA). 4HPR was obtained from Dr Ronald Lubet (National Cancer Institute, Bethesda, MD, USA). The retinoids were dissolved in DMSO at a concentration of 10 mM and stored in the dark at 7808C under N 2 atmosphere. Stock solution was diluted to the appropriate ®nal concentrations with growth medium before use. The caspase inhibitors CBZ-Val-Ala-Asp-FMK (Z-VAD-FMK) and CBZ-AspGlu-Val-Asp-FMK (Z-DEVD-FMK) were purchased from Enzyme System Products (Livermore, CA, USA).
Cells and culture conditions
Human NSCLC cell lines H1792 and H460 were obtained from Dr Adi Gazdar (University of Texas Southwestern Medical Center, Dallas, TX, USA). H460 is a large-cell carcinoma cell line that carries wild-type p53, and H1792 is an adenocarcinoma cell line that carries p53 mutated at intron 6 (GT?AT) (Mitsudomi et al., 1992) . These cells were grown in monolayer culture in a 1 : 1 (v/v) mixture of Dulbecco's modi®ed Eagle's medium and Ham's F12 medium supplemented with 5% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) at 378C in a humidi®ed atmosphere consisting of 5% CO 2 and 95% air.
Cell survival assay
The cells were seeded in 96-well cell culture plates a densities that allowed control cultures to grow exponentially for 4 days. After 24 h, the cells were treated with dierent concentrations of retinoids. Control cultures received the same amount of dimethylsulfoxide (DMSO) as the treated cultures did. After 3 days of treatment, the cell number was estimated by the sulforhodamine B (SRB) assay as described previously (Sun et al., 1997b) .
Apoptosis assay
Cells were plated on either 24-well plates or 10-cm diameter dishes 1 day before treatment. After 24 h treatment with CD437, apoptosis was evaluated by examination of morphological changes by light microscopy, by assessment of cytoplasmic histone-associated DNA fragments (mono-and oligonucleosomes) using an ELISA kit according to the manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN, USA), and by the TUNEL assay using the APO-DIRECT kit (Phoenix Flow Systems, Inc., San Diego, CA, USA) following the manufacturer's protocol.
Cell cycle analysis
Cells were plated on 10-cm diameter dishes 1 day before treatment. After treatment with 1 mM CD437 for dierent times, the cells were harvested by trypsinization, ®xed with cold 70% ethanol, and stored at 48C. The cells were stained with propidium iodide and cell cycle was analysed by¯ow cytometry as described previously (Sun et al., 1997a) Measurement of CPP32-like caspase activation Cells were plated onto 10-cm diameter dishes 1 day before treatment. After the cells were exposed to CD437 for 24 h, both¯oating and attached cells were harvested and counted. Cells (1610 6 ) were used for CPP32-like caspase activity assay using the ApoAlert TM CPP32¯uorescent assay kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions.
cDNA probes GST ± CIP1 plasmid containing human p21 cDNA (Harper et al., 1993) was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). pC53-SN plasmid with wild-type human p53 cDNA was obtained from Dr MQ Hong (the University of Texas MD Anderson Cancer Center, Houston, TX, USA). pCR-Killer-Race-6 plasmid containing human Killer/DR5 cDNA was described before (Wu et al., 1997) . Plasmid containing human TGaseII was purchased from Research Genetics, Inc. (Huntsville, AL, USA). Human Bax cDNA in pSFFVneo vector was provided by Dr SJ Korsmeyer (Washington University School of Medical, Saint Louis, MO, USA). The 1.03 kb EcoRI/XhoI cDNA fragment for p21, 1.80 kb BamHI cDNA fragment for p53, 0.45 kb EcoRI cDNA fragment for Killer/DR5, 0.6 kb EcoRI cDNA fragment for Bax, and 0.8 kb EcoRI/HindIII cDNA fragment for TGaseII were used as probes for Northern blot analysis. The EcoRI/XbaI-digested 340 bp cDNA for GADPH was used to control RNA loading.
RNA puri®cation and Northern blot analysis
Total cellular RNA was puri®ed by the TriReagent method (Molecular Research Center, Inc., Cincinnati, OH, USA). Total RNA (20 mg) was subjected to electrophoresis in a 0.66 M formaldehyde-1.2% agarose gel and then transferred to a Hybond-N membrane (Amersham, Arlington Heights, IL, USA) and UV cross-linked. The cDNA probes were labeled with 32 P-dCTP (ICN Pharmaceuticals Inc., Costa Mesa, CA, USA) to a speci®c activity of approximately 2610 9 c.p.m./mg by the Prime-it II Random Primer Labeling Kit (Stratagene, La Jolla, CA, USA). Following hybridization for 3 h to overnight at 688C in Rapid-Hyb buer (Amersham), the blots were washed once with 16SSC, 0.1% sodium dodecylsulfate (SDS) at room temperature for 20 min. Final washes were done at a stringency of 0.26SSC, 0.1% SDS at 658C for 20 min at least three times. The membranes were then placed against X-ray ®lm (Hyper®lm-MP, Amersham) for autoradiography at 7808C for 1 ± 2 days using double intensifying screens. Quantitation of Northern blot results was done using NIH Image software.
